Publicaciones en colaboración con investigadores/as de Memorial Sloan Kettering Cancer Center (103)

2024

  1. Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes

    Nature Genetics, Vol. 56, Núm. 9, pp. 1878-1889

  2. Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee

    The Lancet Oncology, Vol. 25, Núm. 8, pp. e374-e387

  3. Daratumumab for patients with myeloma with early or late relapse after initial therapy: subgroup analysis of CASTOR and POLLUX

    Blood Advances, Vol. 8, Núm. 2, pp. 388-398

  4. Data-driven, harmonised classification system for myelodysplastic syndromes: a consensus paper from the International Consortium for Myelodysplastic Syndromes

    The Lancet Haematology, Vol. 11, Núm. 11, pp. e862-e872

  5. Efficacy and safety of bendamustine-containing bridging therapy in R/R LBCL patients receiving CD19 CAR T-cells

    HemaSphere, Vol. 8, Núm. 7

  6. Efficacy and safety of regorafenib as a first-line agent alone or in combination with an immune checkpoint inhibitor for advanced hepatocellular carcinoma: a retrospective cohort study

    Journal of Gastrointestinal Oncology, Vol. 15, Núm. 3, pp. 1072-1081

  7. Fine-mapping analysis including over 254,000 East Asian and European descendants identifies 136 putative colorectal cancer susceptibility genes

    Nature Communications, Vol. 15, Núm. 1

  8. Impact of COVID-19 on outcomes with teclistamab in patients with relapsed/refractory multiple myeloma in the phase 1/2 MajesTEC-1 study

    Blood Cancer Journal

  9. International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma

    The Lancet Oncology, Vol. 25, Núm. 5, pp. e205-e216

  10. Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study

    Nature Medicine, Vol. 30, Núm. 8, pp. 2199-2207

  11. Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma

    Blood cancer discovery, Vol. 5, Núm. 3, pp. 146-152

  12. Standardization of the definition of the types of oncological colectomy. Delphi method for consensus of experts of the Spanish Association of Surgeons

    Cirugia Espanola, Vol. 102, Núm. 9, pp. 484-494

2023

  1. A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 29, Núm. 4, pp. 711-722

  2. Adult height and risk of gastric cancer: A pooled analysis within the Stomach cancer Pooling Project

    European Journal of Cancer Prevention, Vol. 32, Núm. 3, pp. 215-221

  3. Author Correction: Deciphering colorectal cancer genetics through multi-omic analysis of 100,204 cases and 154,587 controls of European and east Asian ancestries (Nature Genetics, (2023), 55, 1, (89-99), 10.1038/s41588-022-01222-9)

    Nature Genetics

  4. Comparative Efficacy of Teclistamab Versus Physician's Choice of Therapy in the Long-term Follow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS Clinical Trials in Patients With Triple-class Exposed Relapsed or Refractory Multiple Myeloma

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 23, Núm. 5, pp. 385-393

  5. Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes

    Blood

  6. Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab: part 3 of the open-label, multicenter, phase 1b PAVO study

    Leukemia and Lymphoma

  7. Deciphering colorectal cancer genetics through multi-omic analysis of 100,204 cases and 154,587 controls of European and east Asian ancestries

    Nature Genetics, Vol. 55, Núm. 1, pp. 89-99

  8. Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study

    Blood Advances, Vol. 7, Núm. 14, pp. 3739-3748